title: The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous disease.
abstract: There are a multitude of diseases that commonly affect both the skin and the eye. Part II of this 2-part series reviews the oculocutaneous manifestations of neoplasms, both benign and malignant, and adverse drug reactions affecting the skin and the eye. Though rare, a number of neoplasms that primarily involve the skin, such as melanoma and basal cell carcinoma, can metastasize to the eye, leading to permanent damage if not properly treated. In addition, periocular neoplasms can irritate the conjunctiva and lid, reducing a patient's ability to see clearly. Neoplastic diseases, such as xeroderma pigmentosum, Sturge-Weber syndrome, and multiple myeloma, can also lead to permanent changes in the eye if not discovered and managed promptly. Furthermore, there are a multitude of drugs, including those commonly used by dermatologists, which can result in permanent damage to the eye. With proper knowledge of the ocular manifestations and treatment recommendations described in this 2-part series, dermatologists with the assistance of their ophthalmology colleagues can help avoid the complications, including permanent blindness, associated with infectious, inflammatory, genetic, neoplastic, and drug-related conditions.
authors.affiliation: Texas A&M Health Science Center College of Medicine, College Station, Texas.
authors.forename: Antoinette
authors.initials: A
authors.lastname: Day
authors.affiliation: Baylor University Medical Center, Dallas, Texas.
authors.forename: Amanda K
authors.initials: AK
authors.lastname: Abramson
authors.affiliation: Baylor University Medical Center, Dallas, Texas.
authors.forename: Mahir
authors.initials: M
authors.lastname: Patel
authors.affiliation: The Dermatology Centre, Salford Royal National Health Service Foundation Trust, University of Manchester, Manchester, United Kingdom.
authors.forename: Richard B
authors.initials: RB
authors.lastname: Warren
authors.affiliation: Baylor University Medical Center, Dallas, Texas. Electronic address: amderm@gmail.com.
authors.forename: M Alan
authors.initials: MA
authors.lastname: Menter
mesh_terms: D001017:Aortic Coarctation / Q000175:diagnosis; D002280:Basal Cell Carcinoma / Q000473:pathology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy; D015897:Comorbidity; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000009:adverse effects; D005124:Eye Abnormalities / Q000175:diagnosis; D005128:Eye Diseases / Q000139:chemically induced / Q000453:epidemiology* / Q000209:etiology*; D005142:Eyelid Neoplasms / Q000175:diagnosis / Q000453:epidemiology; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology; D008545:Melanoma / Q000473:pathology; D015580:Mohs Surgery; D009101:Multiple Myeloma / Q000473:pathology / Q000628:therapy; D020752:Neurocutaneous Syndromes / Q000175:diagnosis; D012176:Retinoids / Q000009:adverse effects / Q000627:therapeutic use; D012626:Sebaceous Gland Neoplasms / Q000473:pathology; D012871:Skin Diseases / Q000188:drug therapy / Q000453:epidemiology*; D012878:Skin Neoplasms / Q000473:pathology; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy / Q000453:epidemiology; D013577:Syndrome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D003879:Dermatologic Agents; D012176:Retinoids; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine
keywords: EGFR; PHACES; Stevens-Johnson Syndrome; Sturge Weber Syndrome; basal cell nevus syndrome; cutaneous T-cell lymphoma; drug reactions; inhibitormultiple myeloma; oculocutaneous; periocular neoplasm; toxic epidermal necrolysis; xeroderma pigmentosum